Zymeworks (ZYME) Long-Term Deferred Tax (2021 - 2026)
Zymeworks' (ZYME) quarterly Long-Term Deferred Tax came in at $4.7 million in Q1 2026, down 2.93% year-on-year from $4.8 million in Q1 2025, and little changed quarter-over-quarter from $4.7 million in Q4 2025.
Zymeworks (ZYME) Long-Term Deferred Tax (2021 - 2026) Analysis & Trends
Zymeworks has disclosed Long-Term Deferred Tax across 6 years of filings, most recently posting $4.7 million for Q1 2026.
- Long-Term Deferred Tax for Q1 2026 came in at $4.7 million, down 2.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.7 million (down 2.93% YoY), and the FY2025 annual result was $4.7 million, up 7.34% from the prior year.
- Long-Term Deferred Tax came in at $4.7 million for Q1 2026 at Zymeworks, roughly flat from $4.7 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $4.9 million in Q3 2025 to a low of $1.3 million in Q3 2023.
- The 5-year median for Long-Term Deferred Tax is $3.9 million (2024), against an average of $3.5 million.
- Across the five-year window, Long-Term Deferred Tax sank 56.57% in 2023 and surged 219.85% in 2024, its largest moves.
- Zymeworks' Long-Term Deferred Tax stood at $1.3 million in 2022, then surged by 168.77% to $3.6 million in 2023, then gained by 21.3% to $4.4 million in 2024, then climbed by 7.34% to $4.7 million in 2025, then changed by 0.0% to $4.7 million in 2026.
- The last three Long-Term Deferred Tax figures came in at $4.7 million (Q1 2026), $4.7 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.71 Mn |
| Dec 31, 2025 | 4.71 Mn |
| Sep 30, 2025 | 4.86 Mn |
| Jun 30, 2025 | 4.77 Mn |
| Mar 31, 2025 | 4.85 Mn |
| Dec 31, 2024 | 4.39 Mn |
| Sep 30, 2024 | 4.21 Mn |
| Jun 30, 2024 | 3.95 Mn |
| Mar 31, 2024 | 3.70 Mn |
| Dec 31, 2023 | 3.62 Mn |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.36 Mn |
| Mar 31, 2023 | 1.41 Mn |
| Dec 31, 2022 | 1.35 Mn |
| Sep 30, 2022 | 3.03 Mn |
| Dec 31, 2021 | 3.07 Mn |